

References:

1. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT) [published online ahead of print April 2010]. *Cephalalgia*. doi:10.1177/0333102410367523.
2. Diener H-C, Montagna P, Gács G, et al; on behalf of the Study Group. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. *Cephalalgia*. 2005;26:537-547. doi:10.1111/j.1468-2982.2005.01064.x.
3. Cambia [prescribing information]. Bedminster, NJ: Nautilus Neurosciences Inc; 2010.
4. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? *Headache*. 2002;42(suppl 1):S3-S9.
5. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. *Headache*. 2005;45:850-861.
6. Jakubowski M, Levy D, Kainz V, Zhang X-C, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. *Neuroscience*. 2007;148:573-583.
7. Bigal ME, Serrano D, Buse D, Scher A, Steward WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. *Headache*. 2008;48:1157-1168.
8. Data on file. Nautilus Neurosciences Inc.
9. Migraine medications. MedTRACK Database. Scranton, PA: Life Science Analytics Inc; 2010. www.medtrack.com<<http://www.medtrack.com>>. Accessed March 17, 2010.
10. Data on file. Nautilus Neurosciences Inc.